menu search

GDTC / CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch
CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies. By the end of 2024, CytoMed expects to have human data from two programs and pre-clinical data for its most promising program. Read More
Posted: Sep 1 2023, 20:00
Author Name: Seeking Alpha
Views: 042296

GDTC News  

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch

By Seeking Alpha
September 1, 2023

CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch

CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cell more_horizontal

Why Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?

By InvestorPlace
July 11, 2023

Why Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?

CytoMed Therapeutics (NASDAQ: GDTC ) stock is rocketing higher on Tuesday despite a lack of news concerning the company this morning. Instead of a pre more_horizontal


Search within

Pages Search Results: